<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Surrozen, Inc. — News on 6ix</title>
<link>https://6ix.com/company/surrozen-inc</link>
<description>Latest news and press releases for Surrozen, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 06 May 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/surrozen-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c3da78dffbe2df119ee7.webp</url>
<title>Surrozen, Inc.</title>
<link>https://6ix.com/company/surrozen-inc</link>
</image>
<item>
<title>Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-reports-first-quarter-2026-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-reports-first-quarter-2026-financial-results-and-provides-business-update</guid>
<pubDate>Wed, 06 May 2026 20:05:00 GMT</pubDate>
<description>On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Well-capitalized with $106.9 million in cash and cash equivalents as of March 31, 2026 SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions,</description>
</item>
<item>
<title>Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on</description>
</item>
<item>
<title>Surrozen to Present at Upcoming Healthcare Investor Conference</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-present-upcoming-healthcare-investor-210500635</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-present-upcoming-healthcare-investor-210500635</guid>
<pubDate>Thu, 05 Feb 2026 21:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 Presentation</description>
</item>
<item>
<title>Surrozen to Present at Upcoming Healthcare Investor Conferences</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-present-upcoming-healthcare-investor-210500198</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-present-upcoming-healthcare-investor-210500198</guid>
<pubDate>Tue, 25 Nov 2025 21:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at two upcoming healthcare investor conferences. 37th Annual Piper Sandler Healthcare Conference on December 2, 2025Surrozen Fireside Discussion at 6:30 AM Pacific Time/9:30 AM Eastern T</description>
</item>
<item>
<title>Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-reports-inducement-grant-under-220100108</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-reports-inducement-grant-under-220100108</guid>
<pubDate>Wed, 12 Nov 2025 22:01:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that on November 6, 2025, Surrozen granted inducement stock option awards covering an aggregate of 50,000 shares of Surrozen common stock to the newly appointed Chief Financial Officer, Andrew P. Maleki, as an inducement ma</description>
</item>
<item>
<title>Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-reports-third-quarter-2025-210500977</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-reports-third-quarter-2025-210500977</guid>
<pubDate>Fri, 07 Nov 2025 21:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. Business HighlightsSurrozen remains focused on its ophthalmology pipeline, leveraging its</description>
</item>
<item>
<title>Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-reports-inducement-grants-under-201500660</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-reports-inducement-grants-under-201500660</guid>
<pubDate>Thu, 04 Sep 2025 20:15:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that on September 2, 2025, Surrozen granted inducement stock option awards covering an aggregate of 45,710 shares of Surrozen common stock to four recently hired non-executive employees as an inducement material to their a</description>
</item>
<item>
<title>Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-reports-second-quarter-2025-200500693</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-reports-second-quarter-2025-200500693</guid>
<pubDate>Fri, 08 Aug 2025 20:05:00 GMT</pubDate>
<description>Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and Clinical Trials at the Summit SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wn</description>
</item>
<item>
<title>Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-granted-patent-u-patent-123000717</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-granted-patent-u-patent-123000717</guid>
<pubDate>Wed, 14 May 2025 12:30:00 GMT</pubDate>
<description>Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incorporating novel discoveries related to requirements for efficient and selective Wnt pathway signaling SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt</description>
</item>
<item>
<title>Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-reports-first-quarter-2025-200500052</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-reports-first-quarter-2025-200500052</guid>
<pubDate>Fri, 09 May 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. Business Highlights Surrozen has pivoted its focus to its ophthalmology pipeline, leveraging it</description>
</item>
<item>
<title>Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-provides-fourth-quarter-full-200500342</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-provides-fourth-quarter-full-200500342</guid>
<pubDate>Mon, 31 Mar 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today provided fourth quarter and full year 2024 financial results and business updates. Research and Development Pipeline Highlights The company prioritized its ophthalmology pipeline programs that have the potential</description>
</item>
<item>
<title>Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-announces-oversubscribed-175-million-130000425</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-announces-oversubscribed-175-million-130000425</guid>
<pubDate>Mon, 24 Mar 2025 13:00:00 GMT</pubDate>
<description>Company prioritizes ophthalmology pipeline programs with potential to provide new or improved treatment options in multiple severe and disabling eye diseases Announces an oversubscribed financing of $175 million in gross proceeds, which funds multiple ophthalmology programs through phase 1 safety, tolerability and efficacy studies Company discontinues clinical development of SZN-043 in severe alcohol associated hepatitis SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Surrozen, I</description>
</item>
<item>
<title>Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases </title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-announces-an-oversubscribed-dollar175-million-private-placement-of-securities-to-focus-on-selective-wnt-mimetic-therapeutics-to-treat-serious-eye-diseases</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-announces-an-oversubscribed-dollar175-million-private-placement-of-securities-to-focus-on-selective-wnt-mimetic-therapeutics-to-treat-serious-eye-diseases</guid>
<pubDate>Mon, 24 Mar 2025 04:00:00 GMT</pubDate>
<description>Company prioritizes ophthalmology pipeline programs with potential to provide new or improved treatment options in multiple severe and disabling eye diseases</description>
</item>
<item>
<title>Surrozen Provides Third Quarter 2024 Financial Results and Business Update</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-provides-third-quarter-2024-financial-results-and-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-provides-third-quarter-2024-financial-results-and-business-update</guid>
<pubDate>Wed, 06 Nov 2024 05:00:00 GMT</pubDate>
<description>Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected in the first</description>
</item>
<item>
<title>Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-and-tcgfb-inc-announce-strategic-research-collaboration-to-develop-tgf-b-antibodies-for-idiopathic-pulmonary-fibrosis</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-and-tcgfb-inc-announce-strategic-research-collaboration-to-develop-tgf-b-antibodies-for-idiopathic-pulmonary-fibrosis</guid>
<pubDate>Mon, 04 Nov 2024 05:00:00 GMT</pubDate>
<description>Research collaboration to leverage Surrozen’s antibody research capabilities and expertise to discover a potential first in class treatment for patients with</description>
</item>
<item>
<title>Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-earns-dollar10-million-milestone-payment-in-retinal-diseases-collaboration</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-earns-dollar10-million-milestone-payment-in-retinal-diseases-collaboration</guid>
<pubDate>Tue, 24 Sep 2024 04:00:00 GMT</pubDate>
<description>Boehringer is advancing the development of SZN-413 to prepare it for potential future clinical testing SZN-413 is a bi-specific antibody targeting Frizzled</description>
</item>
<item>
<title>Surrozen Provides Second Quarter 2024 Financial Results and Business Update</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-provides-second-quarter-2024-financial-results-and-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-provides-second-quarter-2024-financial-results-and-business-update</guid>
<pubDate>Mon, 12 Aug 2024 04:00:00 GMT</pubDate>
<description>Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented first-in-human data from SZN-043 Phase 1a trial at EASL</description>
</item>
<item>
<title>Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-presents-preliminary-results-from-phase-1a-study-of-szn-043-in-healthy-volunteers-and-patients-with-a-history-of-liver-cirrhosis-at-the-2024-european-association-for-the-study-of-the-liver-easl-in-milan</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-presents-preliminary-results-from-phase-1a-study-of-szn-043-in-healthy-volunteers-and-patients-with-a-history-of-liver-cirrhosis-at-the-2024-european-association-for-the-study-of-the-liver-easl-in-milan</guid>
<pubDate>Mon, 10 Jun 2024 04:00:00 GMT</pubDate>
<description>SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models Treatment with SZN-043 in</description>
</item>
<item>
<title>Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-initiates-dosing-of-first-patient-in-phase-1b-clinical-trial-of-szn-043-for-severe-alcohol-associated-hepatitis</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-initiates-dosing-of-first-patient-in-phase-1b-clinical-trial-of-szn-043-for-severe-alcohol-associated-hepatitis</guid>
<pubDate>Tue, 04 Jun 2024 04:00:00 GMT</pubDate>
<description>SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1Anticipate potential proof-of-concept data available in the</description>
</item>
<item>
<title>Surrozen Provides First Quarter 2024 Financial Results and Business Update</title>
<link>https://6ix.com/company/surrozen-inc/news/surrozen-provides-first-quarter-2024-financial-results-and-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/surrozen-inc/news/surrozen-provides-first-quarter-2024-financial-results-and-business-update</guid>
<pubDate>Wed, 08 May 2024 04:00:00 GMT</pubDate>
<description>SZN-043 Phase 1a clinical trial results to be presented at the 2024 European Association for the Study of the Liver (EASL) in Milan Preclinical data from ARVO</description>
</item>
</channel>
</rss>